HPV proteins as targets for therapeutic intervention

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 665-678

  Sterlinko Grm, Helena ^a   Banks, Lawrence ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRAL E5 PROTEIN; VIRAL E6 PROTEIN; VIRAL E7 PROTEIN; VIRUS DNA; VIRUS PROTEIN;

DNA REPLICATION; DRUG TARGETING; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; UTERINE CERVIX CANCER; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MICE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 7244245847     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (183)

1. Howley PM & Lowy DR. Papillomaviridae. In Virology, vol. 2 2001; pp. 2197-2264. Edited by BN Fields, JB Knipe & PM Howley. Philadelphia: Lippincott, Williams & Wilkins.
2. zur Hausen H & Schneider A. The Papillomaviruses. In The Papovaviridae: The Papillomaviruses, vol. 2 1987; pp. 245-263. Edited by NP Salzman & PM Howley. New York: Plenum Publishing.
3. Parkin DM, Bray F, Ferlay J & Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001; 94:153-156.
4. Wheeler CM. Clinical aspects and epidemiology of HPV infection. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 1-29. Edited by DJ McCance. Amsterdam: Elsevier Science BV.
5. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R & Shah KV. Prevalence of human papillomavirus in cervical cancer: a world-wide perspective. International biological study on cervical cancer (IBSCC) study group. Journal of the National Cancer Institute 1995; 87:796-801.
6. Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA, McPherson S & Dorin MH. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and Non-Hispanic white women. Journal of the American Medical Association 1994; 271:1181-1188.
7. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D & Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New England Journal of Medicine 1992; 327:1272-1278.
8. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ & Wacholder S. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. Journal of the National Cancer Institute 1993; 85:1868-1870.
9. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ & Meijer CJ; International agency for research on cancer. Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348:518-527.
10. Fuchs PG & Pfister H. Papillomavirus in epidermodysplasia verruciformis. In Papillomavirus Reviews: Current Research on Papillomaviruses, 1996; pp. 253-261. Edited by C Lacey. Leeds, UK: University of Leeds.
11. Benton EC & Arends MJ. Human papillomavirus in the immunosuppressed. In Papillomavirus Reviews: Current Research on Papillomaviruses, 1996; pp. 271-279. Edited by C Lacey. Leeds, UK: University of Leeds.
12. zur Hausen H. Oncogenic DNA viruses. Oncogene Reviews 2001; 20:7820-7823.
13. Stubenrauch F & Laimins LA. Human papillomavirus life cycle: active and latent phases. Seminars in Cancer Biology 1999; 9:379-386.
14. Fehrmann F & Laimins LA. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene Reviews 2003; 22:5201-5207.
15. Doorbar J, Foo C, Coleman N, Medcalf L, Hartley O, Prospero T, Napthine S, Sterling J, Winter G & Griffin H. Characterisation of events during the late stages of HPV16 infection in vivo using high affinity synthetic Fabs to E4. Virology 1997; 238:40-52.
16. Munger K, Phelps WC, Bubb V, Howley PM & Schlegel R. The E6 and E7 genes of human papillomavirus type 16 are necessary and sufficient for transformation of primary human keratinocytes. Journal of Virology 1989; 63:4417-4423.
17. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR & Schiller JT. HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO Journal 1989; 8:3905-3910.
18. Barbosa MS & Schlegel R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989; 4:1529-1532.
19. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R & Howley PM. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. American Journal of Pathology 1985; 119:361-366.
20. Schwarz E, Freese U, Gissmann L, Mayer W, Roggenbuck B, Stremlau A & zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314:111-114.
21. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA & Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. Journal of Virology 1987; 61:962-971.
22. Steele JC. Immunity to human papillomaviruses: implications for vaccine design. In Viruses, Cell Transformation and Cancer, 2001; pp. 451-478. Edited by RJA Grand. Amsterdam: Elsevier Science BV.
23. Breitburd F & Coursaget P. Human papillomavirus vaccines. Seminars in Cancer Biology 1999; 9:431-445.
24. Liu J-S & Melendy T. Human papillomavirus DNA replication. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 53-70. Edited by DJ McCance. Amsterdam: Elsevier Science BV.
25. Yang L, Li R, Mohr I, Clark R & Botchan MR. Activation of BPV-1 replication in vitro by the transcription factor E2. Nature 1991; 353:628-633.
26. Seo Y-S, Muller F, Lusky M, Gibbs E, Kim H-Y, Phillips B. & Hurwitz J. Bovine papilloma virus (BPV)-encoded E2 protein enhances binding of E1 protein to the BPV replication origin. Proceedings of the National Academy of Sciences, USA 1993; 90:2865-2869.
27. Sedman J & Stenlund A. Co-operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomvirus in vivo and in vitro. EMBO Journal 1995; 14:6218-6228.
28. Sedman T, Sedman J & Stenlund A. Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus. Journal of Virology 1997; 71:2887-2896.
29. Faucher AM, White PW, Brochu C, Grand-Maitre C, Rancourt J & Fazal G. Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase. Journal of Medicinal Chemistry 2004; 47:18-21.
30. del Mar Pena L & Laimins LA. Regulation of human papillomavirus gene expression in the vegetative life cycle. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 31-51. Edited by DJ McCance. Amsterdam: Elsevier Science BV
31. Cowsert LM, Fox MC, Zon G & Mirabelli K. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrobial Agents & Chemotherapy 1993; 37:171-177.
32. Clark PR, Roberts ML & Cowsert LM. A novel drug screening assay for papillomavirus specific antiviral activity. Antiviral Research 1998; 37:97-106.
33. Kurg R, Langel U & Ustav M. Inhibition of the bovine papillomavirus E2 protein activity by peptide nucleic acid. Virus Research 2000; 66:39-50.
34. Hajduk PJ, Dinges J, Miknis GF, Merlok M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF & Fesik SW. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. Journal of Medicinal Chemistry 1997; 40:3144-3150.
35. Schaal TD, Mallet WG, McMinn DL, Nguyen NV, Sopko MM, John S & Parekh BS. Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides. Nucleic Acids Research 2003; 31:1282-1291.
36. Kasukawa H, Howley PM & Benson JD. A fifteen-amino-acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro. Journal of Virology 1998; 72:8166-8173.
37. Yoakim C, Ogilvie WW, Goudreau N, Naud J, Hache B, O'Meara JA, Cordingley MG, Archambault J & White PW Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-origin DNA complex. Bioorganic & Medicinal Chemistry Letters Symposia-in-Print 2003; 13:2539-2541.
38. White PW, Titolo S, Brault K, Thauvette L, Pelletier A, Welchner E, Burgon L, Doyon L, Ogilvie WW, Yoakim C, Cordingley MG & Archambault J. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. Journal of Biological Chemistry 2003; 278:26765-26772.
39. Wang Y, Coulombe R, Cameron DR, Thauvette L, Massariol M-J, Amon LM, Fink D, Titolo S, Welchner E, Yoakim C, Archambault J & White PW. Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. Journal of Biological Chemistry 2004; 279:6976-6985.
40. Deng S-J, Pearce KH, Dixon EP, Hartley KA, Stanley TB, Lobe DC, Garvey EP, Kost TA, Petty RL, Rocque WJ, Alexander KA & Underwood MR. Identification of peptides that inhibit the DNA binding, trans-activator, and DNA replication functions of the human papillomavirus type 11 E2 protein. Journal of Virology 2004; 78:2637-2641.
41. Fujii T, Austin D, Guo D, Srimatkandada S, Wang T, Kubushiro K, Masumoto N, Tsukazaki K, Nozawa S & Deisseroth AB. Peptides inhibitory for the transcriptional regulatory function of human papillomavirus E2. Clinical Cancer Research 2003; 9:5423-5428.
42. Chiand C-M, Ustav M, Stenlund A, Ho TF, Broker TR & Chow LT. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proceedings of the National Academy of Sciences, USA 1992; 89:5799-5803.
43. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W & zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO Journal 1984; 3:1151-1157.
44. Pater MM & Pater A. Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology 1985; 145:313-318.
45. Matsukura T, Kanda T, Furuno A, Yoshikawa H, Kawana T & Yoshiike K. Cloning of monomeric human papillomavirus type 16 DNA integrated within cell DNA from a cervical carcinoma. Journal of Virology 1986; 58:979-982.
46. Romanczuk H & Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proceedings of the National Academy of Sciences, USA 1992; 89:3159-3163.
47. Doorbar J. The E4 proteins and their role in the viral life cycle. In Papillomavirus Reviews: Current Research on Papillomaviruses, 1996; pp. 31-38. Edited by C Lacey. Leeds, UK: University of Leeds.
48. Roberts S. Biology of the E4 protein. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 119-142. Edited by DJ McCance. Amsterdam: Elsevier Science BV.
49. 2 arrest domain in the E1/E4 protein of human papillomavirus type 16. Journal of Virology 2002; 76:9806-9818.
50. Roberts S, Hillman ML, Knight GL & Gallimore PH. The NDlO component promyelocytic leukemia protein relocates to human papillomavirus type 1 E4 intranuclear inclusion bodies in cultured keratinocytes and in warts. Journal of Virology 2003; 77:673-684.
51. Peh WL, Brandsma JL, Christensen ND, Cladel NM, Wu X & Doorbar J. The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. Journal of Virology 2004; 78:2142-2151.
52. Doorbar J, Ely S, Sterling J, McLean C & Crawford L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991; 352:824-827.
53. Wang Q, Griffin H, Southern S, Jackson D, Martin A, Mclntosh P, Davy C, Masterson PJ, Walker PA, Laskey P, Omary MB & Doorbar J. Functional analysis of the human papillomavirus type 16 E1/E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. Journal of Virology 2004; 78:821-833.
54. Nakahara T, Nishimura A, Tanaka M, Ueno T, Ishimoto A & Sakai H. Modulation of the cell division cycle by human papillomavirus type 18 E4. Journal of Virology 2002; 76:10914-10920.
55. Leechanachai P, Banks L, Moreau F & Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992; 7:19-25.
56. Leptak C, Cajal R, Kulke SR, Horwitz BH, de Riese D, Dotto GP & DiMaio D. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. Journal of Virology 1991; 65:7078-7083.
57. Pim D, Collins M & Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992; 7:27-32.
58. Straight SW, Hinkle PM, Jewers RJ & McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transform fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. Journal of Virology 1993; 67:4521-4532.
59. Bouvard V, Matlashewski G, Gu ZM, Storey A & Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 1994; 203:73-80.
60. Conrad M, Bubb VJ & Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. Journal of Virology 1993; 67:6170-6178.
61. Schlegel R, Wade-Glass M, Rabson MS & Yang YC. The E5 transforming gene of bovine papillomavirus encodes a small, hydrophobic polypeptide. Science 1986; 233:464-467.
62. Martin P, Vass WC, Schiller JT, Lowy DR & Velu TJ. The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell 1989; 59:21-32.
63. Banks L & Matlashewski G. Biochemical and biological activities of the HPV E5 proteins. In Papillomavirus Reviews: Current Research on Papillomaviruses, 1996; pp. 39-45. Edited by C Lacey. Leeds, UK: University of Leeds.
64. Venuti A & Campo MS. The E5 protein papillomaviruses. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 143-164. Edited by DJ McCance. Amsterdam: Elsevier Science BV.
65. Pim D, Thomas M & Banks L. The function of the human papillomavirus oncogenes. In Viruses, Cell Transformation and Cancer, 2001; pp. 145-192. Edited by RJA Grand. Amsterdam: Elsevier Science BV.
66. DiMaio D & Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene Reviews 2001; 20:7866-7873.
67. Petti L, Nilson LA & DiMaio D. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO Journal 1991; 10:845-855.
68. Petti L & DiMaio D. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. Proceedings of the National Academy of Sciences, USA 1992; 89:6736-6740.
69. Crusius K, Kaszkin M, Kinzel V & Alonso A. The human papillomavirus type 16 E5 protein modulated phospholipase C-gamma-1 activity and phosphatidyl inositol turnover in mouse fibroblasts. Oncogene 1999; 18:6714-6718.
70. Fehrmann F, Klumpp DJ & Laimins LA. Human papillomavirus type 31 E5 protein supports cell cycle progression and activated late viral functions upon epithelial differentiation. Journal of Virology 2003; 77:2819-2831.
71. Genther SM, Sterling S, Duensing S, Munger K, Sattler C & Lambert P. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. Journal of Virology 2003; 77:2832-2842.
72. Bauknecht T, Kohler M, Janz L & Pfleiderer A. The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. Journal of Cancer Research & Clinical Oncology 1989; 115:193-199.
73. Kohler M, Janz I, Wintzer HO, Wagner E & Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Antiviral Research 1989; 9:15371547.
74. Smotkin D & Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proceedings of the National Academy of Sciences, USA 1986; 83:4680-4684.
75. Androphy EJ, Hubbert NL, Schiller JT & Lowy DR. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO Journal 1987; 6:989-992.
76. Banks L, Spence P, Androphy E, Hubbert N, Matlashewski G, Murray A & Crawford L. Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. Journal of General Virology 1987; 68:1351-1359.
77. von Knebel-Doeberitz M, Oltersdorf T, Schwarz E & Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Research 1988; 48:3780-3786.
78. Crook T, Morgenstern JP, Crawford L & Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO Journal 1989; 8:513-519.
79. Storey A, Massimi P, Dawson K & Banks L. Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ-ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. Oncogens 1995; 11:653-661.
80. Goodwin EC &C DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proceedings of the National Academy of Sciences, USA 2000; 97:12513-12518.
81. Hamada K, Sakaue M, Alemany R, Zhang W, Horio Y, Roth J & Mitchell M. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecologic Oncology 1996; 63:219-227.
82. von Knebel Doeberitz M, Rittmuller C, zur Hausen H & Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. International Journal of Cancer 1992; 51:831-834.
83. Alvarez-Salas L, Cullinan A, Siwkowski A, Hampel A & DiPaolo D. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proceedings of the National Academy of Sciences, USA 1998; 95:1189-1194.
84. Hall AHS & Alexsander KA. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. Journal of Virology 2003; 77:6066-6069.
85. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M & Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22:5938-5945.
86. Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T & Yamato K. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Molecular Therapy 2003; 8:762-768.
87. Flores ER, Allen-Hoffmann BL, Lee D & Lambert PF. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. Journal of Virology 2000; 74:6622-6631.
88. Thomas JT, Hubert WG, Ruesch MN & Laimins LA. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proceedings of the National Academy of Sciences, USA 1999; 96:8449-8454.
89. Park RB & Androphy EJ. Genetic analysis of high-risk E6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. Journal of Virology 2002; 76:11359-11364.
90. Oh ST, Longworth MS & Laimins LA. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. Journal of Virology 2004; 78:2620-2626.
91. Thomas M, Pim D & Banks L. Human papillomavirus E6 protein interactions. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 71-99. Edited by DJ McCance. Amsterdam: Elsevier Science BV.
92. McDougall JK. HPV immortalisation and transformation. In Papillomavirus Reviews: Current Research on Papillomaviruses, 1996; pp. 47-53. Edited by C Lacey. Leeds, UK: University of Leeds.
93. Herber R, Liem A, Pitot H & Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. Journal of Virology 1996; 70:1873-1881.
94. Song S, Pitot HC & Lambert PF. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. Journal of Virology 1999; 73:5887-5893.
95. Demers GW, Halbert CL & Galloway DA. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 1994; 198:169-174.
96. Song S, Gulliver GA & Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proceedings of the National Academy of Sciences, USA 1998; 95:2290-2295.
97. White AE, Livanos EM & Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes & Development 1994; 8:666-677.
98. Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, Thompson KJ, DeVries S, Bindley C, Newton MA, Sekhon G & Waldman F. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes & Development 1994; 8:2227-2240.
99. Schaeffer AJ, Nguyen M, Liem A, Lee D, Montagna C, Lambert PF, Ried T & Difilippantonio MJ. E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Research 2004; 64:538-546.
100. Song S, Liem A, Miller JA & Lambert PF. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 2000; 267:141-150.
101. Riley RR, Duensing S, Brake T, Munger K, Lambert PF & Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Research 2003; 63:4862-4871.
102. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, de Villiers EM, Filotico R, Boukamp P & Tommasino M. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. Journal of Virology 2003; 77:2195-2206.
103. Mantovani F & Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene Reviews 2001; 20:7874-7887.
104. Mantovani F & Banks L. The interaction between p53 and papillomaviruses. Seminars in Cancer Biology 1999; 9:387-395.
105. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331.
106. Hansen R & Oren M. p53; from inductive signal to cellular effect. Current Opinion in Genetics & Development 1997; 7:46-51.
107. Crook T, Wrede D & Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991; 6:873-875.
108. Scheffner M, Munger K, Byrne JC & Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proceedings of the National Academy of Sciences, USA 1991; 88:5523-5527.
109. Huibregtse JM, Scheffner M & Howley PM. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Molecular & Cellular Biology 1993; 13:4918-4927.
110. Huibregtse JM, Scheffner M & Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Molecular & Cellular Biology 1993; 13:775-784.
111. Scheffner M, Huibregtse JM, Vierstra RD & Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505.
112. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ & Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proceedings of the National Academy of Sciences, USA 2001; 98:1218-1223.
113. Beer-Romero P, Glass S & Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 1997; 14:595-602.
114. Butz K, Denk C, Ullmann A, Scheffner M & Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proceedings of the National Academy of Sciences, USA 2000; 97:6693-6697.
115. Liu Y, Chen JJ, Gao Q, Dalai S, Hong Y, Mansur CP, Band V & Androphy EJ. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. Journal of Virology 1999; 73:7297-7307.
116. Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K & Kanda T. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology 1995; 212:535-542.
117. Pan H & Griep AE. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes & Development 1995; 9:2157-2169.
118. Pim D, Storey A, Thomas M, Massimi P & Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994; 9:1869-1876.
119. Kivono T, Foster SA, Koop JI, McDougall JK, Galloway DA & Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396:84-88.
120. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T & Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proceedings of the National Academy of Sciences, USA 1997; 94:11612-11616.
121. Elbel M, Carl S, Spaderna S & Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 1997; 239:132-149.
122. Kemp CJ, Donehower LA, Bradley A & Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74:813-822.
123. Chen JJ, Reid CE, Band V & Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995; 269:529-531.
124. Gao Q, Srinivasan S, Boyer SN, Wazer DE & Band V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Molecular & Cellular Biology 1999; 19:733-744.
125. Ronco LV, Karpova AY, Vidal M & Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes & Development 1998; 12:2061-2072.
126. Tong X & Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proceedings of the National Academy of Sciences, USA 1997; 94:4412-4417.
127. Vande Pol SB, Brown MC & Turner CE. Association of bovine papillomavirus type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif. Oncogene 1998; 16:43-52.
128. Be X, Hong Y, Wei J, Androphy EJ, Chen JJ & Baleja JD. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 2001; 40:1293-1299.
129. Chen JJ, Hong Y, Rustamzadeh E, Baleja JD & Androphy EJ. Identification of an alpha helical motif sufficient for association with papillomavirus E6. Journal of Biological Chemistry 1998; 273:13537-13544.
130. Elston RC, Napthine S & Doorbar J. The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. Journal of General Virology 1998; 79:371-374.
131. Nguyen M, Song S, Liem A, Androphy E, Liu Y & Lambert PF. A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. Journal of Virology 2002; 76:13039-13048.
132. Crook T, Tidy JA & Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991; 67:547-556.
133. Nguyen ML, Nguyen MM, Lee D, Griep AE & Lambert PF. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. Journal of Virology 2003; 77:6957-6964.
134. Lee SS, Weiss RS & Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosopbila discs large tumor suppressor protein. Proceedings of the National Academy of Sciences, USA 1997; 94:6670-6675.
135. Nakagawa S & Huibregtse JM. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Molecular & Cellular Biology 2000; 20:8244-8253.
136. Lee SS, Glaunsinger B, Mantovani F, Banks L & Javier RT. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. Journal of Virology 2000; 74:9680-9693.
137. Glaunsinger BA, Lee SS, Thomas M, Banks L & Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000; 19:5270-5280.
138. Gardiol D, Kühne C, Glaunsinger B, Lee SS, Javier R & Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 1999; 18:5487-5496.
139. Morais Cabral JH, Petosa C, Sutcliffe MJ, Raza S, Byron O, Poy F, Marfatia SM, Chishti AH & Liddington RC. Crystal structure of a PDZ domain. Nature 1996; 382:649-652.
140. Doyle DA, Lee A, Lewis J, Kim E, Sheng M & MacKinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell 1996; 85:1067-1076.
141. Hillier BJ, Christopherson KS, Prehoda KE, Bredt DS & Lim WA. Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science 1999; 284:812-815.
142. Sterlinko Grm H, Weber M, Elston R, McIntosh P, Griffin H, Banks L & Doorbar J. Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. Journal of Molecular Biology 2004; 335:971-985.
143. Gross A, McDonnell JM & Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes & Development 1999; 13:1899-1911.
144. Berger SL. Gene activation by histone and factor acetyl-transferases. Current Opinion in Cell Biology 1999; 11:336-341.
145. Goodman RH & Smolik S. CBP/p300 in cell growth, transformation, and development. Genes & Development 2000; 14:1553-1577.
146. Patel D, Huang SM, Baglia LA & McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO Journal 1999; 18:5061-5072.
147. Zimmermann H, Degenkolbe R, Bernard HU & O'Connor MJ. The human papillomavirus type 16 E6 oncoptotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. Journal of Virology 1999; 73:6209-6219.
148. Zimmermann H, Koh CH, Degenkolbe R, O'Connor MJ, Muller A, Steger G, Chen JJ, Lui Y, Androphy E & Bernard HU. Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. Journal of General Virology 2000; 81:2617-2623.
149. Bernat A, Massimi P & Banks L. Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. Journal of General Virology 2002; 83:829-833.
150. Thomas M & Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998; 17:2943-2954.
151. Thomas M & Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. Journal of General Virology 1999; 80:1513-1517.
152. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG & Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. American Journal of Pathology 1994; 145:1323-1336.
153. Krajewski S, Krajewska M & Reed JC. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Research 1996; 56:2849-2855.
154. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR & Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes & Development 1995; 9:2335-2349.
155. Pan H & Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes & Development 1994; 8:1285-1299.
156. Dyson N. The regulation of E2F by pRB-family proteins. Genes & Development 1998; 12:2245-2262.
157. Zwerschke W & Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Advances in Cancer Research 2000; 78:1-29.
158. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M & Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene Reviews 2001; 20:7888-7898.
159. McCance D. The biology of E7. In Perspectives in Medical Virology, 8: Human Papilloma Viruses, 2002; pp. 101-118. Edited by DJ McCance. Amsterdam: Elsevier Science BV.
160. Giarre M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ & Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. Journal of Virology 2001; 75:4705-4712.
161. Gonzalez SL, Stremlau M, He X, Basile JR & Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. Journal of Virology 2001; 75:7583-7591.
162. Lee JO, Russo AA & Pavletich NP. Structure of the cetinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998; 391:859-865.
163. Schmitt A, Harry JB, Rapp B, Wettstein FO & Iftner T. Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. Journal of Virology 1994; 68:7051-7059.
164. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E & Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO Journal 1989; 8:4099-4105.
165. Dick FA, Sailhamer E & Dyson NJ. Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins. Molecular & Cellular Biology 2000; 20:3715-3727.
166. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB & Kaelin WG. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes & Development 1998; 12:95-106.
167. Jewers RJ, Hildebrandt P, Ludlow JW, Kell B & McCance DJ. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. Journal of Virology 1992; 66:1329-1335.
168. Funk JO, Waga S, Harry JB, Espling E, Stillman B & Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes & Development 1997; 11:2090-2100.
169. Jones DL, Alani RM & Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes & Development 1997; 11:2101-2111.
170. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW & Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13:2323-2330.
171. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM & Dotto GP. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proceedings of the National Academy of Sciences, USA 1995; 92:5451-5455.
172. Helt AM, Funk JO & Galloway DA. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. Journal of Virology 2002; 76:10559-10568.
173. Smotkin D & Wettstein FO. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. Journal of Virology 1987; 61:1686-1689.
174. Firzlaff JM, Luscher B & Eisenman RN. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proceedings of the National Academy of Sciences, USA 1991; 88:5187-5191.
175. Firzlaff JM, Galloway DA, Eisenman RN & Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biologist 1989; 1:44-53.
176. Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR & Vousden KH. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO Journal 1990; 9:153-160.
177. Massimi P, Pim D, Kuhne C & Banks L. Regulation of the human papillomavirus oncoproteins by differential phosphorylation. Molecular & Cellular Biochemistry 2001; 227:137-144.
178. Massimi P & Banks L. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology 2000; 276:388-394.
179. Massimi P, Pim D, Storey A & Banks L. HPV-16 E7 and adenovirus EIa complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996; 12:2325-2330.
180. Chien WM, Parker JN, Schmidt-Grimminger DC, Broker TR & Chow LT. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry. Cell Growth & Differentiation 2000; 11:425-435.
181. Banks L, Edmonds C & Vousden KH. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 1990; 5:1383-1389.
182. Watanabe S, Kanda T, Sato H, Furuno A & Yoshiike K. Mutational analysis of human papillomavirus type 16 E7 functions. Journal of Virology 1990; 64:207-214.
183. Reinstein E, Scheffner M, Oren M, Ciechanover A & Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 2000; 19:5944-5950.